Literature DB >> 19622627

Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial.

Roderick F A de Lind van Wijngaarden1, Dederieke A M Festen, Barto J Otten, Edgar G A H van Mil, Joost Rotteveel, Roelof J Odink, Mariëtte van Leeuwen, Danny A J P Haring, Gianni Bocca, E C A Mieke Houdijk, Anita C S Hokken-Koelega.   

Abstract

BACKGROUND: Bone mineral density (BMD) is unknown in children with Prader-Willi syndrome (PWS), but is decreased in adults with PWS. In patients with GH deficiency, BMD increases during GH treatment.
OBJECTIVES: The aim of the study was to evaluate BMD in children with PWS and to study the effects of GH treatment.
DESIGN: We conducted a randomized controlled GH trial. Forty-six prepubertal children were randomized into either a GH-treated group (1.0 mg/m(2) . d) or a control group for 2 yr. At start, 6, 12, and 24 months of study, total body and lumbar spine BMD were measured by dual-energy x-ray absorptiometry, and lumbar spine bone mineral apparent density (BMAD) was calculated.
RESULTS: Baseline total body and lumbar spine BMD sd score (SDS) were normal [mean (sd), -0.2 SDS (1.1) and -0.4 SDS (1.2), respectively]. BMADSDS, which corrects for short stature, was also normal [mean (sd), 0.40 SDS (1.1)]. Total body BMDSDS decreased during the first 6 months of GH (P < 0.0001), but increased during the second year of treatment. After 24 months of study, total body and lumbar spine BMDSDS, and the BMADSDS did not significantly differ between GH-treated children and randomized controls (P = 0.30, P = 0.44, and P = 0.47, respectively). Results were similar when corrected for body mass index SDS. Repeated measurements analysis showed a significant positive association between IGF-I SDS and total body and lumbar spine BMDSDS, but not with BMADSDS.
CONCLUSIONS: Our results show that prepubertal children with PWS have a normal BMD. GH treatment had no effect on BMD, except for a temporary decrease of total body BMDSDS in the first 6 months.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622627     DOI: 10.1210/jc.2009-0270

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Review of Prader-Willi syndrome: the endocrine approach.

Authors:  Ryan Heksch; Manmohan Kamboj; Kathryn Anglin; Kathryn Obrynba
Journal:  Transl Pediatr       Date:  2017-10

2.  Growth hormone in health and disease: Prader-Willi syndrome--GH therapy and bone.

Authors:  Graziano Grugni
Journal:  Nat Rev Endocrinol       Date:  2013-04-09       Impact factor: 43.330

3.  Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome.

Authors:  T N Hangartner; D F Short; T Eldar-Geva; H J Hirsch; M Tiomkin; A Zimran; V Gross-Tsur
Journal:  Osteoporos Int       Date:  2016-07-04       Impact factor: 4.507

Review 4.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

5.  The genetic background and vitamin D supplementation can affect irisin levels in Prader-Willi syndrome.

Authors:  M F Faienza; G Brunetti; G Grugni; D Fintini; A Convertino; P Pignataro; A Crinò; S Colucci; M Grano
Journal:  J Endocrinol Invest       Date:  2021-03-03       Impact factor: 5.467

6.  Endocrine manifestations and management of Prader-Willi syndrome.

Authors:  Jill E Emerick; Karen S Vogt
Journal:  Int J Pediatr Endocrinol       Date:  2013-08-21

Review 7.  Prader-Willi syndrome and growth hormone deficiency.

Authors:  Zehra Aycan; Veysel Nijat Baş
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014

Review 8.  Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Authors:  Graziano Grugni; Alessandro Sartorio; Antonino Crinò
Journal:  Ther Clin Risk Manag       Date:  2016-06-02       Impact factor: 2.423

9.  Prader-Willi Critical Region, a Non-Translated, Imprinted Central Regulator of Bone Mass: Possible Role in Skeletal Abnormalities in Prader-Willi Syndrome.

Authors:  Ee-Cheng Khor; Bruce Fanshawe; Yue Qi; Sergei Zolotukhin; Rishikesh N Kulkarni; Ronaldo F Enriquez; Louise Purtell; Nicola J Lee; Natalie K Wee; Peter I Croucher; Lesley Campbell; Herbert Herzog; Paul A Baldock
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

Review 10.  Irisin and Secondary Osteoporosis in Humans.

Authors:  Roberta Zerlotin; Angela Oranger; Patrizia Pignataro; Manuela Dicarlo; Filippo Maselli; Giorgio Mori; Silvia Concetta Colucci; Maria Grano; Graziana Colaianni
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.